Vanguard Capital Management’s Damora Therapeutics DMRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.9M Buy
557,495
+344,895
+162% +$9.8M ﹤0.01% 2664
2026
Q2
$5.53M Buy
212,600
+10,753
+5% +$260K ﹤0.01% 3081
2026
Q1
$5.23M Buy
+201,847
New +$5.19M ﹤0.01% 3041

Other funds holding DMRA

Vanguard Capital Management's DMRA Position: Q3 2026 in Review

Vanguard Capital Management increased its Damora Therapeutics (DMRA) stake by 162% in Q3 2026, buying an estimated $9.8M and bringing the position to 557,495 shares worth $11.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2664.

Vanguard Capital Management first reported a position in DMRA in Q1 2026 and has held it in 3 quarters since. 115 funds tracked by Wall St. Rank hold DMRA as of Q3 2026.

  • Vanguard Capital Management held 557,495 shares of Damora Therapeutics worth $11.9M as of Q3 2026.
  • Vanguard Capital Management bought 344,895 Damora Therapeutics shares in Q3 2026, an estimated $9.8M.
  • Damora Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2664 holding.
  • Vanguard Capital Management first reported a position in Damora Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 115 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.